[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"grant-kwf-biomarkers-2026-clinical-validation-of-biomarkers":3,"similar-kwf-biomarkers-2026-clinical-validation-of-biomarkers":35},{"id":4,"name":5,"funder":6,"link":7,"budget":8,"budget_min_eur":9,"budget_max_eur":10,"deadline":11,"deadline_note":12,"duration":13,"trl":14,"relevance":11,"why_relevant":11,"early_career":15,"consortium":16,"first_seen":17,"last_updated":11,"update_note":11,"status":18,"stages":19,"call_frequency":11,"next_call_expected":11,"source_url":7,"created_at":20,"updated_at":21,"eligible_countries":22,"description":24,"seo_summary":25,"links":26},"kwf-biomarkers-2026-clinical-validation-of-biomarkers","Biomarkers 2026 — Clinical Validation of Biomarkers","KWF","https:\u002F\u002Fwww.kwf.nl\u002Fen\u002Fforresearchers\u002Ffunding\u002Fbiomarkers2026","€0.8M–€2M per proposal (total call budget €4M–€6M)",800000,2000000,null,"Full proposal deadline was 14 April 2026 (12:00 noon); funding decision July 2026 — call appears closed","2–5 years","5-6",false,"Required — minimum 4 participating parties (multidisciplinary consortium; private partners allowed)","2026-07-01T00:00:00.000Z","open","2-stage: pre-proposal (closed 2 Dec 2025) → full proposal (closed 14 Apr 2026) → interviews (Jun 2026)","2026-07-01T05:09:47.147Z","2026-07-01T06:05:19.739Z",[23],"NL","Multidisciplinary consortium (≥4 parties) to clinically validate known cancer biomarkers at TRL5\u002F6 for near-term clinical practice. Mandatory components: (early) HTA, patient involvement (PACO review 30% weight), FAIR data-sharing plan, project manager. For-profit partners >250 FTE must co-finance 10% of KWF budget. All cancer types in scope; biomarkers for treatment side-effects are out of scope.","{\"summary\":\"The Biomarkers 2026 call funds €0.8-€2 million per consortium over 2-5 years for clinical validation of cancer biomarkers at TRL5-6, moving known markers toward near-term clinical practice. Applicants must form multidisciplinary consortia of at least four parties (including academic, hospital, patient groups, and optional industry) based in the Netherlands. This is a closed call (deadline 14 April 2026, funding decision July 2026); KWF runs similar biomarker validation calls periodically.\",\"meta_description\":\"Biomarkers 2026 funds cancer biomarker clinical validation by Dutch consortia up to €2M over 2-5 years, closed call, from KWF.\",\"who_should_apply\":[\"Consortia of ≥4 parties: academic researchers, hospital clinicians, patient representatives, and optional industry partners\",\"Researchers and clinicians based in the Netherlands\",\"Teams with a known cancer biomarker at TRL5-6 ready for clinical translation\",\"Projects that include HTA, patient co-design (PACO), a data-sharing plan, and a dedicated project manager\",\"For-profit partners with >250 FTE must be prepared to co-finance 10% of the KWF budget\"],\"key_dates\":[\"Pre-proposal deadline: 2 December 2025 (closed)\",\"Full proposal deadline: 14 April 2026 (closed)\",\"Interviews: June 2026; funding decision: July 2026\",\"Project duration: 2-5 years\"],\"tips\":[\"PACO (patient review) carries 30% weight, embed patient co-investigators and lived-experience input throughout the proposal narrative, not as an afterthought.\",\"The mandatory HTA (health technology assessment) must be credible from proposal stage; partner with someone experienced in Dutch HTA frameworks or ISPOR methods.\",\"Data-sharing plans must be FAIR-compliant and explicit about which data, when, and to whom; vague commitments fail review. Name the repository and governance structure.\"],\"faq\":[{\"q\":\"How much does the Biomarkers 2026 call fund?\",\"a\":\"€0.8-€2 million per consortium, with a total call budget of €4-€6 million.\"},{\"q\":\"What type of consortium do I need for Biomarkers 2026?\",\"a\":\"A multidisciplinary consortium of at least 4 parties, including academic, clinical, patient, and optionally industry partners; for-profit partners with >250 FTE must co-finance 10% of the KWF budget.\"},{\"q\":\"Which biomarkers are eligible for Biomarkers 2026?\",\"a\":\"Known cancer biomarkers at TRL5-6 for any cancer type, focused on near-term clinical practice validation; biomarkers for treatment side-effects are not eligible.\"},{\"q\":\"Is Biomarkers 2026 a rolling or annual call?\",\"a\":\"KWF runs periodic biomarker validation calls; Biomarkers 2026 is now closed. Check the KWF website for the next round.\"},{\"q\":\"What is PACO and why is it important for this grant?\",\"a\":\"PACO is patient and caregiver co-review, which carries 30% weight in evaluation. Patient representatives must be meaningfully embedded in the consortium and research design.\"}],\"tags\":[\"cancer-biology\",\"kwf\",\"biomarker-validation\",\"translational-research\",\"consortium-required\",\"netherlands\",\"clinical-implementation\",\"patient-involvement\"]}",{"matchedProgram":11,"resourceSlug":27,"relatedGuides":28,"countryHubs":29,"domainHubs":33,"closingMonth":11,"hasRelated":34,"hasBrowseRelated":34},"kwf",[],[30],{"slug":31,"demonym":32},"nl","Dutch researchers",[],true,{"grants":36},[37,41,45,49,53],{"id":38,"name":39,"funder":6,"deadline":17,"budget":40},"kwf-boost-bridging-obstacles-for-optimal-model-use-via-2026-07","BOOST (Bridging Obstacles for Optimal model use via Shared Technical expertise)","~€150,000 per project",{"id":42,"name":43,"funder":6,"deadline":44,"budget":11},"kwf-boost-2026","Boost-2026","2026-07-07T00:00:00.000Z",{"id":46,"name":47,"funder":6,"deadline":44,"budget":48},"kwf-pipeline-2026-07","Pipeline","€1–5M",{"id":50,"name":51,"funder":6,"deadline":44,"budget":52},"kwf-pipeline-2027","Kwf Pipeline 2027","€1-5M per proposal (indicative)",{"id":54,"name":55,"funder":6,"deadline":44,"budget":56},"kwf-pipeline-2026","KWF Pipeline Call 2026","€1M-€5M"]